Holen Sie sich die Stockscreener-App
52.51
4.54%
2.24
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$50.27
Offen:
$50.93
24-Stunden-Volumen:
789.14K
Relative Volume:
0.35
Marktkapitalisierung:
$8.23B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
55.86
EPS:
0.94
Netto-Cashflow:
$245.03M
1W Leistung:
+2.20%
1M Leistung:
+5.33%
6M Leistung:
-33.24%
1J Leistung:
-32.43%
1-Tages-Spanne:
$50.68
$53.56
1-Wochen-Bereich:
$49.71
$53.89
52-Wochen-Spanne:
$46.01
$83.62
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
52.52 | 8.25B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.28 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.75 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.29 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio Techne Corporation Stock Analysis and ForecastFree Investment Community - Autocar Professional
Bio-Techne Corporation shares rise 1.99% after-hours as US stocks close higher. - AInvest
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch
Envestnet Asset Management Inc. Sells 66,478 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne’s Quarterly Earnings Preview: What You Need to Know - inkl
Bio-Techne Schedules Q4 2025 Earnings Call: Full Fiscal Year Results Coming August 6 - Stock Titan
Bio-Techne’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
Bio-Techne to distribute Spear Bio’s ultrasensitive immunoassays - Yahoo Finance
Bio-Techne Corp (NASDAQ:TECH) Stake Lessened by M&T Bank Corp - Defense World
Analysts Set Bio-Techne Corp (NASDAQ:TECH) Price Target at $70.00 - Defense World
Why Bio Techne Corporation stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
How Bio Techne Corporation stock performs during market volatilityFree Expert-Led Investment Training - Newser
What makes Bio Techne Corporation stock price move sharplyOptimized Return Investment Picks - Newser
Here’s Headwaters Capital Management’s Investment Thesis for Bio-Techne (TECH) - Yahoo Finance
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access By Investing.com - Investing.com South Africa
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access - Investing.com
Bio-Techne Secures 1000x More Sensitive Biomarker Detection Technology in Major Neuroscience Partnership - Stock Titan
Bio-Techne (TECH) Partners with Spear Bio for Advanced Biomarker Detection | TECH Stock News - GuruFocus
Revolutionary Alzheimer's Biomarker Detection: Bio-Techne's New Platform Achieves 1000x Higher Sensitivity - Stock Titan
Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection - Yahoo Finance
Bio-techne’s technology supports FDA approval of rare skin disorder therapy - Investing.com
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy - Yahoo Finance
Teacher Retirement System of Texas Makes New Investment in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Principal Financial Group Inc. - Defense World
Teacher Retirement System of Texas Acquires New Holdings in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Scotiabank Has Lowered Expectations for Bio-Techne (NASDAQ:TECH) Stock Price - Defense World
Bio-Techne stock price target lowered to $75 by Scotiabank - Investing.com Canada
TD Cowen Begins Coverage on Bio-Techne (NASDAQ:TECH) - Defense World
Minnesota's highest-paid CEOs made 7% more, with highest paid making $59.4M - Star Tribune
Assessing Bio-Techne: Insights From 7 Financial Analysts - Benzinga
Bio-Techne (TECH) Receives Buy Rating with $65 Price Target from TD Cowen | TECH Stock News - GuruFocus
Bio-Techne (TECH): TD Cowen Initiates Coverage with Buy Rating | - GuruFocus
Vontobel Holding Ltd. Decreases Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
GAMMA Investing LLC Cuts Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Amalgamated Bank Purchases 222 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)? - Yahoo Finance
How To Trade (TECH) - news.stocktradersdaily.com
Janney Montgomery Scott LLC Grows Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock - Zacks Investment Research
Bio-Techne stock holds steady as Stifel maintains $60 price target - Investing.com
Is Bio-Techne Stock Underperforming The Nasdaq? - Barchart.com
Major Breakthrough: Bio-Techne and USP Join Forces to Transform Gene Therapy Development Process - Stock Titan
First Week of August 15th Options Trading For Bio-Techne (TECH) - Nasdaq
Bio-Techne (NASDAQ:TECH) stock performance lags Nasdaq Composite in recent years - Kalkine Media
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
How the (TECH) price action is used to our Advantage - news.stocktradersdaily.com
Bio-Techne Director Cashes Out in Significant Stock Sale - TipRanks
Bio-Techne at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Techne Corp-Aktie (TECH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
Jun 09 '25 |
Option Exercise |
44.33 |
1,280 |
56,742 |
3,256 |
| Herr Amy E. | Director |
Jun 09 '25 |
Sale |
49.77 |
1,280 |
63,705 |
1,976 |
0.39%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):